Cagrilintide + Retatrutide
Also known as: Cagri + Reta · Cagrilintide/Retatrutide blend
A research blend pairing the long-acting amylin analog cagrilintide with the triple-receptor agonist retatrutide, discussed in the context of appetite and metabolic regulation.
Class
Amylin analog + triple-receptor agonist blend
Default unit
mg
Common route
Subcutaneous
Typical half-life
Long-acting (both components support weekly dosing)
Frequency
Once weekly
Commonly associated areas
Illustrative map of the body systems Cagrilintide + Retatrutide is most often discussed in relation to. Relative emphasis only — not a measure of efficacy or a medical claim.
Proposed mechanisms / pathways
What is Cagrilintide + Retatrutide?
Cagrilintide + Retatrutide is a research blend that pairs two distinct molecules. Cagrilintide is a long-acting amylin analog — a synthetic version of the satiety hormone amylin. Retatrutide is an investigational triple-receptor agonist that activates the GLP-1, GIP, and glucagon receptors at once. The pairing brings together amylin-pathway and incretin-pathway signaling in a single protocol, and both components are long-acting enough to support a once-weekly cadence.
How it is thought to work
The two components are thought to act on complementary appetite and metabolic pathways. Cagrilintide is reported to engage amylin signaling associated with satiety and slowed gastric emptying, while retatrutide adds incretin and glucagon activity discussed in the context of appetite, blood-sugar handling, and energy expenditure. The idea behind combining them is overlapping routes to appetite regulation rather than any single mechanism. These effects remain under active investigation and are not established.
Educational only — not medical advice
This is an investigational blend of two compounds that have not been approved for general human use and remain in research settings. Nothing here is a recommendation, dose, or medical claim — consult a qualified healthcare provider before considering any protocol.
Tracking Cagrilintide + Retatrutide in LynkDose
Because both parts of this blend are usually titrated and their effects overlap, careful record-keeping matters. In LynkDose, log each weekly dose with its date, mark when a dose increases, keep a consistent weekly weigh-in, and note appetite changes and any side effects. With that history, a plateau or a reaction becomes something you can actually see and discuss rather than guess at.
Commonly discussed for
- Appetite and craving regulation
- Weight-management research protocols
- Combined satiety and metabolic markers
Often stacked: This is itself a combination — cagrilintide paired with retatrutide — so it is the blend rather than a single compound, and it is generally studied as the pairing rather than stacked further.
How to track Cagrilintide + Retatrutide in LynkDose
Because both components are typically titrated and the two effects overlap, log every weekly dose with its date and mark each dose change, alongside a consistent weekly weigh-in and appetite notes, so changes can be tied to a specific step.
Deeper read: Tracking GLP-1 Peptides (Semaglutide & Tirzepatide)
Frequently asked questions
What is Cagrilintide + Retatrutide?
A research blend pairing the long-acting amylin analog cagrilintide with the triple-receptor agonist retatrutide, discussed in the context of appetite and metabolic regulation.
What is Cagrilintide + Retatrutide commonly used for?
Cagrilintide + Retatrutide is most commonly discussed in the context of appetite and craving regulation, weight-management research protocols, and combined satiety and metabolic markers. This is educational context, not medical advice.
How do you track Cagrilintide + Retatrutide?
Because both components are typically titrated and the two effects overlap, log every weekly dose with its date and mark each dose change, alongside a consistent weekly weigh-in and appetite notes, so changes can be tied to a specific step.
Is Cagrilintide + Retatrutide approved or medically recommended?
No. This page is educational only and is not medical advice. Many peptides are research compounds not approved for general human use. Always consult a qualified healthcare provider before making health decisions.
Research & references
For primary research and chemical data, search these databases. Entries here are educational summaries, not citations of specific findings.
Not medical advice
This page is educational and does not recommend, prescribe, or dose any compound. Many peptides are research chemicals not approved for general human use. Always consult a qualified healthcare provider and follow the laws in your area.